TY - JOUR
T1 - Multidisciplinary approach for hypothalamic obesity in children and adolescents
T2 - A preliminary study
AU - Tessaris, Daniele
AU - Matarazzo, Patrizia
AU - Tuli, Gerdi
AU - Tuscano, Antonella
AU - Rabbone, Ivana
AU - Spinardi, Alessandra
AU - Lezo, Antonella
AU - Fenocchio, Giorgia
AU - Buganza, Raffaele
AU - De Sanctis, Luisa
N1 - Publisher Copyright:
© 2021 by the authors.
PY - 2021/7
Y1 - 2021/7
N2 - Hypothalamic obesity (HO) is delineated by an inexorable weight gain in subjects with hypothalamic disorder (congenital or acquired). The aim of the present study was to evaluate the effect of a multidisciplinary approach on weight trend and metabolic outcome in children and adolescents with hypothalamic disease who were overweight or obese. Thirteen patients (aged 8.1– 16.1 years) received a personalized diet, accelerometer-based activity monitoring, and psychological assessment. Height, weight, body mass index (BMI), and serum metabolic parameters were assessed at baseline (T0) and after six months (T1). Metformin was introduced at T1 in four subjects who were then re-evaluated after six months (T2). At T1, weight gain was significantly reduced compared with T0 (0.29 + 0.79 kg/month vs. 0.84 + 0.55 kg/month, p = 0.03), and weight standard deviation score (SDS) and BMI SDS did not change significantly, as serum metabolic parameters. The four subjects treated with metformin showed a reduction of weight SDS and BMI SDS at T2. In conclusion, patients treated with our multidisciplinary approach showed, after 6 months, favorable results characterized by decreased weight gain and stabilization of weight SDS and BMI SDS in a condition usually characterized by inexorable weight gain. However, further analysis, larger cohorts, and longer follow-up are needed to confirm these preliminary data.
AB - Hypothalamic obesity (HO) is delineated by an inexorable weight gain in subjects with hypothalamic disorder (congenital or acquired). The aim of the present study was to evaluate the effect of a multidisciplinary approach on weight trend and metabolic outcome in children and adolescents with hypothalamic disease who were overweight or obese. Thirteen patients (aged 8.1– 16.1 years) received a personalized diet, accelerometer-based activity monitoring, and psychological assessment. Height, weight, body mass index (BMI), and serum metabolic parameters were assessed at baseline (T0) and after six months (T1). Metformin was introduced at T1 in four subjects who were then re-evaluated after six months (T2). At T1, weight gain was significantly reduced compared with T0 (0.29 + 0.79 kg/month vs. 0.84 + 0.55 kg/month, p = 0.03), and weight standard deviation score (SDS) and BMI SDS did not change significantly, as serum metabolic parameters. The four subjects treated with metformin showed a reduction of weight SDS and BMI SDS at T2. In conclusion, patients treated with our multidisciplinary approach showed, after 6 months, favorable results characterized by decreased weight gain and stabilization of weight SDS and BMI SDS in a condition usually characterized by inexorable weight gain. However, further analysis, larger cohorts, and longer follow-up are needed to confirm these preliminary data.
KW - BMI
KW - Hypothalamic obesity
KW - Metformin
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=85113829601&partnerID=8YFLogxK
U2 - 10.3390/children8070531
DO - 10.3390/children8070531
M3 - Article
SN - 2227-9067
VL - 8
JO - Children
JF - Children
IS - 7
M1 - 531
ER -